IRG1/itaconate alleviates acute liver injury in septic mice by suppressing NLRP3 expression and its mediated macrophage pyroptosis via regulation of the Nrf2 pathway
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112277 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Pei Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022,China. Hauptthemen laut MEDLINE: Macrophages, Mice, Inbred C57BL, NF-E2-Related Factor 2, NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Sepsis, a systemic inflammatory response triggered by infection, has a considerably high mortality rate. However, effective prevention and intervention measures against sepsis remain insufficient. Therefore, this study aimed to investigate the mechanisms underlying the protective properties of immune response gene-1 (IRG1) and 4-Octyl itaconate (OI) during acute liver damage in mice with sepsis. A sepsis mouse model was established to compare wild-type and IRG1-/- groups. The impact of IRG1/Itaconate on pro- and anti-inflammatory cytokines was evaluated using J774A.1 cells. IRG1/Itaconate substantially reduced pro-inflammatory cytokines and increased the release of anti-inflammatory cytokines. It reduced pathological damage to liver tissues, preserved normal liver function, decreased the release of reactive oxygen species (ROS) and LDH, and enhanced the GSH/GSSG ratio. Moreover, IRG1 and itaconic acid activated the Nrf2 signaling pathway, regulating the expression of its downstream antioxidative stress-related proteins. Additionally, they inhibited the activity of NLRP3 inflammatory vesicles to suppress the expression of macrophage-associated pyroptosis signaling molecules. Our findings demonstrate that IRG1/OI inhibits NLRP3 inflammatory vesicle activation and macrophage pyroptosis by modulating the Nrf2 signaling pathway, thereby attenuating acute liver injury in mice with sepsis. These findings could facilitate the clinical application of IRG1/Itaconate to prevent sepsis-induced acute liver injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022,China.
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022,China. Electronic address: kaixiongtao@hust.edu.cn.
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022,China. Electronic address: zhangpeng_xt@hust.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, P., Yang, L., Li, R., Yin, Y., Xie, G., Liu, X., Shi, L., Tao, K., & Zhang, P. (2024). IRG1/itaconate alleviates acute liver injury in septic mice by suppressing NLRP3 expression and its mediated macrophage pyroptosis via regulation of the Nrf2 pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112277
Vancouver
Zhou P, Yang L, Li R, Yin Y, Xie G, Liu X, et al. IRG1/itaconate alleviates acute liver injury in septic mice by suppressing NLRP3 expression and its mediated macrophage pyroptosis via regulation of the Nrf2 pathway. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112277
BibTeX
@article{Zhou2024,
author = {Zhou, Pei and Yang, Lei and Li, Ruidong and Yin, Yuping and Xie, Gengchen and Liu, Xinghua and Shi, Liang and Tao, Kaixiong and Zhang, Peng},
title = {IRG1/itaconate alleviates acute liver injury in septic mice by suppressing NLRP3 expression and its mediated macrophage pyroptosis via regulation of the Nrf2 pathway},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112277}
}
EUVIMED